JAK inhibitor plus aminosalicylate

This page covers all JAK inhibitor plus aminosalicylate drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting JAK1/JAK3 (tofacitinib); unclear specific target for mesalamine (likely prostaglandin-related).

Targets

JAK1/JAK3 (tofacitinib); unclear specific target for mesalamine (likely prostaglandin-related)

Marketed (1)

• Tofacitinib plus mesalamine · Post Graduate Institute of Medical Education and Research, Chandigarh · Immunology / Gastroenterology
  Tofacitinib inhibits JAK kinases to reduce inflammatory signaling, while mesalamine acts as a topical anti-inflammatory in the colon.

Patent intelligence

• jak inhibitor plus aminosalicylate patent landscape — aggregated cliff calendar, attackable patents, originator estates